UCLA Medical Center

Santa Monica, California 90404

2 studies enrolling now · 20 studies all time

What they study most

Advanced Cancer, Advanced Hepatocellular Carcinoma, Advanced Non-Small Cell Lung Cancer, Breast Cancer, Breast Neoplasms, CRC, Cancer, Cancer Weight Loss, Cholangiocarcinoma, Colorectal Cancer, EGFR-mutated NSCLC (Disorder), Esophagogastric Cancer

Studies at this site

• Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy — Recruiting now
• Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing — Recruiting now
• Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma — Running, not enrolling
• A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer — Running, not enrolling
• A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy — Running, not enrolling
• A Study to Investigate LYL845 in Adults With Solid Tumors — Stopped early
• Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer — Completed
• A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors — Stopped early
• A Study of CFI-400945 Fumarate in Patients With Advanced Cancer — Completed
• Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma — Completed
• A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens — Completed
• MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC — Stopped early
• Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) — Completed
• A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma — Completed
• A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors — Completed
• A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies — Completed
• Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors — Completed
• TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy — Stopped early
• Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer — APPROVED_FOR_MARKETING